Una puesta al día fundamental | 12 JUL 21

Dolor neuropático

Diagnóstico y tratamiento no intervencionista del dolor neuropático
INDICE:  1. Texto principal | 2. Referencias bibliográficas
Referencias bibliográficas
  1. 1.Treede, R. D., et al. (2008). Neuropathic pain: Redefinition and a grading system for clinical and research purposes. Neurology, 70(18), 1630–1635.
  2. van Hecke, O., et al. (2014). Neuropathic pain in the general population: A systematic review of epidemiological studies. Pain, 155(4), 654–662.
  3. Baron, R., Binder, A., & Wasner, G. (2010). Neuropathic pain: Diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurology, 9(8), 807– 819.
  4. Colloca, L., et al. (2017). Neuropathic pain. Nature Reviews. Disease Primers, 3, 17002.
  5. van Hecke, O., et al. (2015). Neuropathic pain phenotyping by international consensus (NeuroPPIC) for genetic studies: A NeuPSIG systematic review, Delphi survey, and expert panel recommendations. Pain, 156(11), 2337– 2353.
  6. Finnerup, N. B., et al. (2016). Neuropathic pain: An updated grading system for research and clinical practice. Pain, 157(8), 1599–1606.
  7. Maier, C., et al. (2010). Quantitative sensory testing in the German research network on neuropathic pain (DFNS): Somatosensory abnormalities in 1236 patients with different neuropathic pain syndromes. Pain, 150(3), 439–450.
  8. Westermann, A., et al. (2011). Pain-associated mild sensory deficits without hyperalgesia in chronic non-neuropathic pain. The Clinical Journal of Pain, 27(9), 782–789.
  9. Backonja, M. M., et al. (2013). Value of quantitative sensory testing in neurological and pain disorders: NeuPSIG consensus. Pain, 154(9), 1807– 1819.
  10. Cruccu, G., et al. (2010). EFNS guidelines on neuropathic pain assessment: Revised 2009. European Journal of Neurology, 17(8), 1010–1018.
  11. Haanpaa, M., et al. (2011). NeuPSIG guidelines on neuropathic pain assessment. Pain, 152(1), 14–27.
  12. Lauria, G., et al. (2010). European Federation of Neurological Societies/ peripheral nerve society guideline  on  the  use  of  skin  biopsy  in  the diagnosis of small fiber neuropathy. Report of a joint task  force of  the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur.J.Neurol., 17(7), 903–909.
  13. Garcia-Larrea, L., et al. (2002). Laser-evoked potential abnormalities in central pain patients: The influence of  spontaneous  and  provoked  pain.  Brain, 125(Pt 12), 2766–2781.
  14. Valeriani, M., et al. (2012). Clinical usefulness of laser evoked potentials.

Neurophysiologie Clinique, 42(5), 345–353.

  1. Omori, S., et al. (2017). Pain-related evoked potentials after intraepidermal electrical stimulation to Adelta and C fibers in patients  with  neuropathic pain. Neuroscience Research, 121, 43–48.
  2. Hansen, N., et al. (2015). Amplitudes of pain-related evoked potentials are useful to detect small fiber involvement in painful mixed fiber neuropathies        in addition to quantitative sensory testing - an electrophysiological study. Frontiers in Neurology, 6, 244.
  3. Cruzat, A., Qazi, Y., & Hamrah, P. (2017). In vivo confocal microscopy of corneal nerves in health and disease. The Ocular Surface, 15(1), 15–47.
  4. Ziegler, D.,  et al. (2014). Early detection  of nerve  fiber loss by corneal confocal microscopy and skin biopsy in recently diagnosed type 2 diabetes. Diabetes, 63(7), 2454–2463.
  5. Chen, X., et al. (2015). Small nerve fiber quantification in the diagnosis of diabetic sensorimotor polyneuropathy: Comparing corneal confocal microscopy with intraepidermal nerve fiber density. Diabetes Care, 38(6), 1138–1144.
  6. Weidner, C., et al. (2000). Acute effects of substance P and calcitonin gene- related peptide in human skin--a microdialysis study. The Journal of Investigative Dermatology, 115(6), 1015–1020.
  7. Fuller, R. W., et al. (1987). Sensory neuropeptide effects in human skin. British Journal of Pharmacology, 92(4), 781–788.
  8. Kramer, H. H., et al. (2004). Electrically stimulated axon reflexes are diminished in diabetic small fiber neuropathies. Diabetes, 53(3), 769–774.
  9. Bickel, A., et al. (2009). C-fiber axon reflex flare size correlates with epidermal nerve fiber density in human skin biopsies. Journal of the Peripheral Nervous System, 14(4), 294–299.
  10. Kalliomaki, M., et al. (2011). Structural and functional differences between neuropathy with and without pain? Experimental Neurology, 231(2), 199–206.
  11. Schley, M., et al. (2012). Skin innervation at different depths correlates with small fibre function but not with pain in neuropathic  pain patients. European Journal of Pain, 16(10), 1414–1425.
  12. Bickel, A., et al. (2002). Assessment of the neurogenic flare reaction in small- fiber neuropathies. Neurology, 59(6), 917–919.
  13. Green, A. Q., Krishnan, S. T., & Rayman, G. (2009). C-fiber function assessed by the laser doppler imager flare  technique  and  acetylcholine iontophoresis. Muscle & Nerve, 40(6), 985–991.
  14. Koppert, W., et al. (2004). Mechanically induced axon reflex and hyperalgesia  in human UV-B burn are reduced by systemic lidocaine. European Journal of Pain, 8(3), 237–244.
  15. Krishnan, S. T., & Rayman, G. (2004). The LDIflare: A novel test of C-fiber function demonstrates early neuropathy in type 2 diabetes. Diabetes Care, 27(12), 2930–2935.
  16. Kubasch, M. L., et al. (2017). Laser Doppler assessment of vasomotor axon reflex responsiveness to evaluate neurovascular function. Frontiers in Neurology, 8, 370.
  17. Unal-Cevik, I. (2018). Temporal and spatial quantification of pain- related small fiber functionality assessed using laser speckle contrast analysis. Pain Practice, 18(7),:824–838.
  18. Freynhagen, R., et al. (2006). painDETECT: A new screening questionnaire to identify neuropathic  components  in  patients  with  back  pain.  Current Medical Research and Opinion, 22(10), 1911–1920.
  19. Bouhassira, D., et al. (2005). Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain, 114(1–2), 29–36.
  20. Bennett, M. (2001). The LANSS pain scale: The Leeds assessment of neuropathic symptoms and signs. Pain, 92(1–2), 147–157.
  21. Bouhassira, D., et al. (2004). Development and validation of the neuropathic pain symptom inventory. Pain, 108(3), 248–257.
  22. Galer, B. S., & Jensen, M. P. (1997). Development and preliminary validation of a pain measure specific to neuropathic pain: The neuropathic pain scale. Neurology, 48(2), 332–338.
  23. Chaparro, L. E., et al. (2012). Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database of Systematic Reviews, (7), Cd008943.
  24. Wiffen, P. J., et al. (2017). Gabapentin for chronic neuropathic pain in adults.

Cochrane Database of Systematic Reviews, 6, Cd007938.

  1. Finnerup, N. B., et al. (2015). Pharmacotherapy for  neuropathic  pain  in adults: A systematic review and meta-analysis. Lancet Neurology, 14(2), 162– 173.
  2. Waldfogel, J. M., et al. (2017). Pharmacotherapy for diabetic peripheral neuropathy pain and quality of life: A systematic review. Neurology, 88(20), 1958–1967.
  3. Wiffen, P. J., et al. (2014). Carbamazepine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews, (4), Cd005451.
  4. Griebeler, M. L., et al.  (2014).  Pharmacologic  interventions  for  painful diabetic neuropathy: An umbrella systematic review and comparative effectiveness network meta-analysis. Annals of Internal Medicine, 161(9), 639– 649.
  5. Thomas, A. M., & Atkinson, T. J. (2018). Old friends with new faces: Are Sodium Channel blockers the future of adjunct pain medication management? The Journal of Pain, 19(1), 1–9.
  6. Zhou, M., et al. (2017). Oxcarbazepine for neuropathic pain. Cochrane Database of Systematic Reviews, 12, Cd007963.
  7. Snedecor, S. J., et al. (2014). Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy. Pain Practice, 14(2), 167–184.
  8. Demant, D. T., et al. (2014). The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: A randomised, double-blind, placebo-controlled phenotype-stratified study. Pain, 155(11), 2263–2273.
  9. Sindrup, S. H., et al. (2017). Impact of etiology and duration of pain on pharmacological treatment effects in painful polyneuropathy. European Journal of Pain, 21(8), 1443–1450.
  10. Min, K., et al. (2016). Symptom-based treatment of  neuropathic  pain  in spinal cord-injured patients: A randomized crossover clinical trial. American Journal of Physical Medicine & Rehabilitation, 95(5), 330–338.
  11. Holbech, J. V., et al. (2016). Pain phenotype as a predictor for drug response  in painful polyneuropathy-a retrospective analysis of data from controlled clinical trials. Pain, 157(6), 1305–1313.
  12. Thienel, U., et al. (2004). Topiramate in painful diabetic polyneuropathy: Findings from three double-blind placebo-controlled trials. Acta Neurologica Scandinavica, 110(4), 221–231.
  13. Wiffen, P. J., et al. (2013). Topiramate for neuropathic pain and fibromyalgia   in adults. Cochrane Database of Systematic Reviews, (8), Cd008314.
  14. Wiffen, P. J., et al. (2013). Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews. Cochrane Database of Systematic Reviews, (11), Cd010567.
  15. Wiffen, P. J., Derry, S., & Moore, R. A. (2013). Lamotrigine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews, (12), Cd006044.
  16. Hearn, L., Derry, S., & Moore, R. A. (2012). Lacosamide for neuropathic pain and fibromyalgia in adults. Cochrane.Database.Syst.Rev., 2, CD009318.
  17. Birse, F., Derry, S., & Moore, R. A. (2012). Phenytoin for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews, (5), Cd009485.
  18. Saudek, C. D., Werns, S., & Reidenberg, M. M. (1977). Phenytoin in the treatment of diabetic symmetrical polyneuropathy. Clinical  Pharmacology and Therapeutics, 22(2), 196–199.
  19. Chadda, V. S., & Mathur, M. S. (1978). Double blind study of the effects of diphenylhydantoin sodium on diabetic neuropathy. The Journal of the Association of Physicians of India, 26(5), 403–406.
  20. Moore, R. A., et al. (2015). Amitriptyline for neuropathic pain in adults.

Cochrane Database of Systematic Reviews, (7), Cd008242.

  1. Derry, S., et al. (2015). Nortriptyline for neuropathic pain in adults. Cochrane Database of Systematic Reviews, 1, Cd011209.
  2. Hearn, L., et al. (2014). Imipramine for neuropathic pain in adults. Cochrane Database of Systematic Reviews, (5), Cd010769.
  3. Goldstein, D. J., et al. (2005). Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain, 116(1–2), 109–118.
  4. Raskin, J., et al. (2005). A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Medicine, 6(5), 346–356.
  5. Wernicke, J. F., et al. (2006). A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology, 67(8), 1411–1420.
  6. Sultan, A., et al. (2008). Duloxetine for painful diabetic neuropathy and fibromyalgia pain: Systematic review of randomised trials. BMC Neurology, 8, 29.
  7. Ney, J. P., et al. (2013). Comparative efficacy of oral pharmaceuticals for the treatment of chronic peripheral neuropathic pain: Meta-analysis and indirect treatment comparisons. Pain Medicine, 14(5), 706–719.
  8. Kajdasz, D. K., et al. (2007). Duloxetine for the management of diabetic peripheral neuropathic  pain: Evidence-based  findings from post hoc analysis  of three multicenter, randomized, double-blind, placebo-controlled, parallel- group studies. Clinical Therapeutics, 29(Suppl), 2536–2546.
  9. Boyle, J., et al. (2012). Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: Impact on pain, polysomnographic sleep, daytime functioning, and quality of life. Diabetes Care, 35(12), 2451–2458.
  10. Lunn, M. P., Hughes, R. A., & Wiffen, P. J. (2014). Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database of Systematic Reviews, (1), Cd007115.
  11. Lindner, V., & Deuschl, G. (2004). Antidepressants and anticonvulsive agents. Practical utility profile in pain therapy. Schmerz, 18(1), 53–60.
  12. Derry, S., et al. (2015). Milnacipran for neuropathic pain in adults. Cochrane Database of Systematic Reviews, (7), Cd011789.
  13. Gallagher, H. C., et al. (2015). Venlafaxine for neuropathic pain in adults.

Cochrane Database of Systematic Reviews, (8), Cd011091.



Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2023